Abstract:Ischemic stroke is a leading cause of death and disability worldwide. Advances in early recognition of stroke symptoms and the transport of patients to specialized stroke centers has been a major step in improvement of mortality and morbidity. Speed is essential since current intravenous thrombolytic treatments can only be delivered in a very narrow therapeutic window. Intravenous therapy requires specialized skills, subjects the medication to first pass metabolism, and the issue of blood to brain transport is a major problem. An alternate approach, the intranasal route, could deliver medication to the target in a quick manner and overcome the blood brain barrier to the central nervous system while avoiding first pass metabolism. Intranasal medication also requires minimal skill to administer in a hospital or in the field. This chapter will address the pathway through which substances travel from the nasal epithelium to various regions of the central nervous system. This includes multiple substances for intranasal administration for the potential treatment of ischemic stroke, such as proteins and peptides, stem cells, gene vectors and nanoparticles. The chapter will conclude with the merits and potential issues of intranasal administration, as well as future directions.

Intranasal Delivering Method in the Treatment of Ischemic Stroke